What can we help you with?

Services Phases

Services

Affinity Selection Mass SpectrometryAffinity Selection Mass SpectrometryCovalent Binding AssaysCovalent Binding AssaysProteomics & ChemoproteomicsProteomics & ChemoproteomicsSmall Molecule AnalysisSmall Molecule AnalysisOligo AnalysisOligo AnalysisData ProductsData ProductsView All ServicesView All Services

Phases

Target Discovery & ValidationTarget Discovery & ValidationLead GenerationLead GenerationLead Selection & OptimizationLead Selection & OptimizationPreclinical StudiesPreclinical StudiesBiomarker Discovery, Development & AnalysisBiomarker Discovery, Development & AnalysisView All PhasesView All Phases

What can we help you with?

Modalities Therapeutic Areas

Modalities

RadiotherapeuticsRadiotherapeuticsMolecular GluesMolecular GluesTargeted Protein DegradersTargeted Protein DegradersCovalent DrugsCovalent DrugsDNA- and RNA-Targeting DrugsDNA- and RNA-Targeting DrugsOligonucleotide TherapeuticsOligonucleotide TherapeuticsKinase InhibitorsKinase InhibitorsView All ModalitiesView All Modalities

Therapeutic Areas

OncologyOncologyImmunologyImmunologyNeuroscienceNeuroscienceMetabolic DiseaseMetabolic DiseaseInfectious DiseaseInfectious DiseaseRare DiseasesRare DiseasesView All Therapeutic AreasView All Therapeutic Areas

What can we help you with?

Technologies Platforms Expertise

Technologies

CHIPPCHIPPCysScout™CysScout™DecryptMDecryptMKinomeScout™KinomeScout™NucleoBeads™NucleoBeads™PhotoTargetScout™PhotoTargetScout™PlasmaScout™PlasmaScout™Protein Turnover Atlas™Protein Turnover Atlas™Proteome Atlas™Proteome Atlas™ProteomeScout™ProteomeScout™QuantScout™QuantScout™SignalingScout™SignalingScout™SPICESPICESurfaceScout™SurfaceScout™TargetScout™TargetScout™TurnoverScout™TurnoverScout™UbiScout™UbiScout™View All TechnologiesView All Technologies

Platforms

RapidFire-MSRapidFire-MSICP-MSICP-MSOrbitrap Astral ZoomOrbitrap Astral ZoomOrbitrap AscendOrbitrap AscendView All PlatformsView All Platforms

Expertise

Compound Management & Chemical LibrariesCompound Management & Chemical LibrariesScreening LaboratoryScreening LaboratoryBiochemistry & Chemical BiologyBiochemistry & Chemical BiologyCell & Molecular BiologyCell & Molecular BiologyMS-based ProteomicsMS-based ProteomicsComputational BiologyComputational BiologyProject ManagementProject ManagementView All ExpertiseView All Areas of Expertise

Explore Our Resource Library

September 24, 2026
•Blog Posts

Eileen Ablondi, PhD

TAC Attack!: The Extended Universe of Targeted Protein Degraders

Targeted protein degradation (TPD) has emerged as a key strategy for the development of small-molecule therapeutics, leveraging clever chemistries to induce the specific degradation of protein targets. Early molecular glues relied on the serendipitous discovery of molecules capable of modulating the stability of protein-protein interactions (PPIs).  In 2001, the initial report of Proteolysis-Targeting Chimeras (PROTACs) introduced a transformative framework:   heterobifunctional molecules designed such that a moiety binding a protein target is connected via flexible linker to an E3...

August 6, 2026
•Posters

Zane Thistleford, Christina Thompson, William LaMarr, Can Ozbal, Jan Kubicek & Barbara Maertens

Investigation of Hits against the GLP-1 Receptor Identified by Affinity Selection Mass Spectrometry: Hit Expansion, Structure-Activity Relationships, and Selectivity Profiling

Small molecule engagement of the GLP-1 receptor using affinity selection mass spectrometry (ASMS) proved to be a productive starting point for drug discovery, with a 50,000 compound diversity screen identifying three structurally distinct hit series that could be expanded and characterized in depth. Hit expansion across 52 analogs established clear structure-activity relationships within 3 scaffolds.

February 27, 2026
•Blog Posts

Eileen Ablondi

Native MS in Drug Discovery & Development

In this month’s blog post, we’re spotlighting one of our newest service lines – Native MS. This powerful technology is...

Sign up for News & Updates